Hugh Goodfellow > Carpmaels & Ransford LLP > London, England > Lawyer Profile

“Managing partner Hugh Goodfellow is a notable member of the team with significant expertise in representing both well-established and growing biotechnology companies in prosecution proceedings” (The Legal 500, 2025). He has an “expansive practice” (IAM Patent 1000) with clients ranging from large and long-established global companies (e.g. Janssen, Takeda, Bristol Myers Squibb, Regeneron and Vertex) through to growing biotech companies (e.g., Akari, Radius Health, Hubrecht Organoid Technology, Translate Bio and Westway Health). During his career, he has been responsible for establishing the filing strategy and generating IP portfolios for a number of start-ups, guiding some of these clients all the way from early conception, through financing rounds and subsequent public flotation. His particular area of current focus includes biologics – in particular, therapeutic antibodies, complex immunology, biosimilar defence work and stem cell technology. Collectively, these experiences have developed Hugh’s ability to consistently and successfully protect foundation intellectual property and forecast potential future problems from the viewpoint of both IP generation and freedom to operate. Hugh has been noted as a “top-tier advisor” who “seamlessly links the firm’s prosecution division with its dispute resolution arm” He is cited as a “trusted IP adviser with valuable global insight” whose ability to navigate the complexities of the patent landscape makes him an invaluable source of knowledge and an excellent leader of the practice. (IAM Patent 1000).

Hugh received his BA (Hons) in Biochemistry and his MA and DPhil from the University of Oxford. His experience at the bench was spent investigating mechanisms of drug resistance in cancer cells.